Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Tissue-specific tumor microenvironments influence responses to immunotherapies.

Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, Beavis PA, House IG, Van Audernaerde JR, Darcy PK, Kershaw MH, Slaney CY.

Clin Transl Immunology. 2019 Nov 21;8(11):e1094. doi: 10.1002/cti2.1094. eCollection 2019.

2.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.

House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA.

Clin Cancer Res. 2020 Jan 15;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. Epub 2019 Oct 21.

3.

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression.

Mardiana S, Solomon BJ, Darcy PK, Beavis PA.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaaw2293. doi: 10.1126/scitranslmed.aaw2293. Review.

PMID:
31167925
4.

Switching on the green light for chimeric antigen receptor T-cell therapy.

Mardiana S, Lai J, House IG, Beavis PA, Darcy PK.

Clin Transl Immunology. 2019 May 5;8(5):e1046. doi: 10.1002/cti2.1046. eCollection 2019. Review.

5.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

6.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

7.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

8.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

Supplemental Content

Loading ...
Support Center